Clinical trial
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
NCT00322673 · Symphony Evolution, Inc., Industry · Terminated
Key facts
| NCT number | NCT00322673 |
|---|---|
| Title | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) |
| Official title | A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia |
| Lead sponsor | Symphony Evolution, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, AML |
| Intervention type | Drug |
| Interventions | XL999 |
| Enrollment | 14 |
| Start date | May 1, 2006 |
| Primary completion | Nov 1, 2006 |
| Completion | May 1, 2007 |
| First posted | May 8, 2006 |
| Last update posted | Feb 22, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: